TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36243020
Drug: Chronic convection-enhanced
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic convection-enhanced delivery of topotecan (146 μM, 200 μL/h for 48 h, followed by a 5-7 day washout period, with four total infusions)
Study: 35466448
Drug: Romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 210 mg sc monthly
Study: 35466448
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg po weekly
Study: 34431612
Drug: Scalp acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp acupuncture (ISSA) at parietal midline [MS5], left anterior parietotemporal oblique line [MS6], left posterior parietotemporal oblique line [MS7] for one course of treatment.
Study: 34431612
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine (control group).
Study: 35184471
Drug: Nomogram for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram for predicting poor ovarian response (POR) based on factors such as age, infertility type, body mass index, anti-Müllerian hormone, basal follicle stimulating hormone, basal estrogen, antral follicle number, previous times of POR, history of ovarian surgery, ovulation stimulation protocol, average amount of gonadotropin.
Study: 35498888
Drug: Corticosteroids combined
Normalized name: combinations of corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids combined with renin‐angiotensin system blockers (RASBs)
Study: 33590955
Drug: 2400 mg
Normalized name: pancreatin 2400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg Aged Garlic Extract (AGE) daily for 1 year
Study: 34990291
Drug: Two cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of concurrent 100 mg/m2 DDP
Study: 34990291
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of concurrent DDP
Study: 33797427
Drug: Depo‐Medrol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo‐Medrol (40 mg/1 cc)
Study: 33797427
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline 1 cc)
Study: 32571395
Drug: Miao crossbow
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miao crossbow needle therapy (CN)
Study: 34365776
Drug: Metformin or
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin or sulfonylurea/metformin combination (Group 1)
Study: 34365776
Drug: Thiazolidinedione combination
Normalized name: 2,4-thiazolidinedione
DrugBank: 2,4-thiazolidinedione (DB11898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinedione combination (Group 2)
Study: 34365776
Drug: Dipeptidyl peptidase‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipeptidyl peptidase‐4 inhibitor (gemigliptin) combination (Group 3)
Study: 34365776
Drug: Sodium‐glucose cotransporter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium‐glucose cotransporter 2 inhibitor (empagliflozin) combination (Group 4)
Study: 36152018
Drug: Oral function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral function intervention (one-on-one lesson on oral exercise and preventive oral care)
Study: 33025730
Drug: Pomalidomide 2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 2.6 mg/m2 (MTD) given orally once daily for 21 consecutive days of a 28-day cycle
Study: 33025730
Drug: Pomalidomide 3.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 3.4 mg/m2 (dose level 3)
Study: 32693653
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic cream (5% lidocaine‐prilocaine cream)
Study: 32009473
Drug: Cryo-immuno-therapy (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryo-immuno-therapy (combination of cryotherapy with intralesional Candida antigen)
Study: 32009473
Drug: Intralesional Candida
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Candida antigen monotherapy
Study: 33177808
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dezocine and sufentanil (1:3, 1:1, 3:1)
Study: 35294135
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicines
Study: 35125219
Drug: MAS-1 adjuvanted
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAS-1 adjuvanted IIV (1, 3, 5, or 9 µg per HA)
Study: 35125219
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose IIV (Fluzone SD, 15 µg per HA)
Study: 33762179
Drug: Comprehensive lifestyle-medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive lifestyle-medical treatment to targets and PET guided interventions
Study: 32241789
Drug: True acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: True acupuncture treatment (10 sessions, five sessions per week for 2 weeks)
Study: 32241789
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment (10 sessions, five sessions per week for 2 weeks)
Study: 34825770
Drug: Intralesional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroid with QR678 Neo®
Study: 34825770
Drug: Intralesional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroid alone
Study: 35940251
Drug: 5-hydroxytryptophan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxytryptophan (100 mg oral, twice daily for 8 weeks)
Study: 32701419
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU, n=47)
Study: 34153143
Drug: Clazakizumab (anti-IL-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab (anti-IL-6 antibody)
Study: 35195306
Drug: Oral 50
Normalized name: fat supplement, oral 50% oral emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 50 mg Zoledronic acid (ZA) once-a-week for 6 weeks
Study: 34420816
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg a day
Study: 36287389
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg 1% lidocaine (0.15 ml/kg)
Study: 36287389
Drug: 0.15 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 ml/kg 0.9% NaCl (placebo)
Study: 35596730
Drug: LA-cookie (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-cookie (10 g grapeseed oil per day)
Study: 35596730
Drug: OA-cookie (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OA-cookie (10 g high oleate safflower oil per day)
Study: 34310352
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (swabs and BS)
Study: 32719258
Drug: Sequential boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential boost (SEQB)
Study: 33212063
Drug: Patisiran 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran 0.3 mg/kg by intravenous infusion every 3 weeks
Study: 33065589
Drug: Delayed-Release Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Delayed-Release Linaclotide 30 μg
Study: 33065589
Drug: Delayed-Release Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Delayed-Release Linaclotide 100 μg
Study: 33065589
Drug: Delayed-Release Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Delayed-Release Linaclotide 300 μg
Study: 33065589
Drug: MD-7246 (formerly
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD-7246 (formerly DR2) 30 μg
Study: 33065589
Drug: MD-7246 (formerly
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD-7246 (formerly DR2) 100 μg
Study: 33065589
Drug: MD-7246 (formerly
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD-7246 (formerly DR2) 300 μg
Study: 33065589
Drug: Immediate-Release Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immediate-Release Linaclotide 290 μg
Study: 35160076
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of 20% albumin administered after induction of anesthesia
Study: 32429851
Drug: Galcanezumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab (both doses combined)
Study: 35122766
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) maintenance therapy
Study: 32338316
Drug: Transdermal granisetron
Normalized name: granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal granisetron (granisetron patch replaced every 7 days)
Study: 32338316
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron (8 mg thrice daily for 72 hours after chemotherapy)
Study: 32338316
Drug: Transdermal granisetron
Normalized name: granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal granisetron
Study: 32338316
Drug: Transdermal granisetron
Normalized name: granisetron Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal granisetron and Oral ondansetron
Study: 34280468
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin plus GLP-1RA
Study: 34280468
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin plus daily gliflozin pill
Study: 33687988
Drug: Flexible subcutaneous
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible subcutaneous catheter
Study: 33314016
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality therapy (VRT) Armeo Spring® upper limb exoskeleton (Armeo), 45 minutes daily for 3 weeks
Study: 33314016
Drug: Conventional physiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physiotherapy, 45 minutes daily for 3 weeks
Study: 35197360
Drug: Aducanumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aducanumab (30 mg/kg single dose)
Study: 35197360
Drug: Aducanumab (3-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aducanumab (3-10 mg/kg)
Study: 36112019
Drug: Doxycycline hyclate
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline hyclate injected at the implant-abutment interface
Study: 36398746
Drug: Conventional Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Physical Therapy (CPT), n=5
Study: 34605959
Drug: Yohimbine (alpha2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (alpha2-receptor blocker)
Study: 35806857
Drug: 3.6 g
Normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g sodium butyrate daily for 12 weeks
Study: 34051877
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg twice per day for 3 days, then once per day for 27 days)
Study: 33331570
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (Dex) treatment during surgery
Study: 33331570
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (Dex) treatment
Study: 34890047
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (CC) 100 mg/day
Study: 34890047
Drug: Letrozole (L)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (L) 5 mg/day
Study: 34890047
Drug: Letrozole (L)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (L) 2.5 mg/day + Clomiphene Citrate (CC) 50 mg/day
Study: 35274407
Drug: Euthymic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euthymic therapy (active control)
Study: 34354699
Drug: Multidrug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidrug therapy (MDT) comprising rifampicin, dapsone, and clofazimine, 12 doses
Study: 32151918
Drug: 12-week exercise
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week exercise program combining weekly group sessions and home-based exercises (2/week) focusing on motor learning, flexibility, strengthening, and balance.
Study: 35525784
Drug: Social-physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social-physical activity program (2 weekly sessions of 1 hour of physical exercise for 4 months; monthly sessions on healthy habits; 3 days of social activities)
Study: 35435875
Drug: Benson relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benson relaxation technique combined with music therapy
Study: 32630191
Drug: Lixisenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (10 mcg)
Study: 35263280
Drug: Intratracheal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal oxygen administration
Study: 35263280
Drug: Intranasal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal oxygen administration
Study: 34119270
Drug: Combined cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined cilostazol and aspirin therapy
Study: 33452064
Drug: Early model
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early model variables (HIE severity, epinephrine administration, respiratory support, fraction of inspired oxygen of 0.21 at admission)
Study: 33452064
Drug: Cumulative model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative model variables (Severity of EEG findings, HIE severity, use of steroids for blood pressure management, significant brain injury on MRI)
Study: 34215800
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin applied to the left upper back
Study: 34215800
Drug: Placebo topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical cream applied to the left upper back
Study: 33168545
Drug: Abatacept 125
Normalized name: abatacept 125 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept 125 mg weekly subcutaneous for 169 days
Study: 32014238
Drug: Participant-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant-controlled intravenous rehydration with 4% dextrose in 0.18% sodium chloride, bolus volumes of 50 ml (low volume) or 200 ml (high volume), triggered by thirst.
Study: 36228777
Drug: Medications-first arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medications-first arm
Study: 39215872
Drug: Carnosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine (2 g/day)
Study: 34986012
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT), 1500 mJ/cm2, three sessions/week for 4 weeks
Study: 34986012
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy (ESWT), 0.05 mJ/mm2, one session/week for 4 weeks
Study: 35485674
Drug: Omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omega 3 (flaxseed oil) 1gm three times daily for 3 months
Study: 35485674
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose capsule) for 3 months
Study: 32513111
Drug: Caudal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ropivacaine plus 0.25 mg/kg ketamine (Group K0.25)
Study: 32513111
Drug: Caudal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ropivacaine plus 0.5 mg/kg ketamine (Group K0.5)
Study: 32513111
Drug: Caudal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ropivacaine plus 0.75 mg/kg ketamine (Group K0.75)
Study: 32513111
Drug: Caudal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal ropivacaine plus 1.0 mg/kg ketamine (Group K1.0)
Study: 616388369
Drug: Routine nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine nursing treatment
Study: 33122168
Drug: Aprepitant (15-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (15-40 kg: 80 mg on days 1-3; >40 kg: 125 mg on day 1, 80 mg on days 2-3)
Study: 33122168
Drug: Ondansetron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.15 mg/kg every 8 hours for 8 days)
Study: 33612484
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin infusion (0.05 Unit/kg/hour)
Study: 33612484
Drug: Standard-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose insulin infusion (0.1 Unit/kg/hour)
Study: 33597521
Drug: TV003 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV003 vaccine
Study: 34118470
Drug: CAD/CAM device
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAD/CAM device (Narval CC™)
Study: 35273351
Drug: BNT162b2 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 mRNA COVID‐19 vaccine
Study: 33550995
Drug: Transdiagnostic psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic psychological therapy (n = 527)
Study: 33550995
Drug: Treatment-as-usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (TAU) (n = 534)
Study: 35984511
Drug: Heated humidified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated humidified high-flow nasal cannula (HFNC) oxygen therapy
Study: 35984511
Drug: Traditional nasal
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional nasal catheter oxygen therapy
Study: 34217960
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of echinacea angustifolia, twice daily
Study: 34217960
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of echinacea angustifolia, twice daily
Study: 33168881
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment (CTL)
Study: 32401086
Drug: IANB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IANB with additional buccal infiltration
Study: 32401086
Drug: Buccal and
Normalized name: Buprenorphine and Naloxone Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal and lingual anaesthetic infiltration (INF)
Study: 34453212
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous somatostatin (250 μg/h over 120 h); n=99
Study: 34941128
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of a 2% saline solution for bilateral nasal irrigation for 1 week, followed by 50 mL of a 0.9% normal saline solution for bilateral nasal irrigations.
Study: 34941128
Drug: Routine guidance
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine guidance and 20 mL of normal saline atomized through inhalation.
Study: 35039254
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine Paishi decoction combined with laparoscopic ureterectomy
Study: 34703056
Drug: ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultrasound guided SCPB with 5 mL ropivacaine 0.5%
Study: 34374434
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) with adjunctive amoxicillin (500 mg) and metronidazole (200 mg) three times a day for 7 days
Study: 34110746
Drug: Combination oral
Normalized name: PROBIOTIC COMBINATION ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oral nitroimidazole 500 mg twice a day for 7 days and simultaneous boric acid 600 mg daily per vagina for 30 days, followed by twice-weekly vaginal metronidazole gel for 5 months.
Study: 34110746
Drug: Maintenance metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance metronidazole gel
Study: 32903261
Drug: Oral stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral stimulation program (tactile extra-, peri-, and intraoral manipulation) once a day for 15 minutes over 10 days
Study: 616901046
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOACs) such as rivaroxaban and edoxaban
Study: 33494795
Drug: Acetate Ringer’s
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate Ringer’s solution
Study: 34032376
Drug: Passive pedaling
Normalized name: orange peel extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive pedaling with mini bike, 20 min, twice a week for 3 months
Study: 34157617
Drug: OxCapRT (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxCapRT (oxaliplatin 85 mg/m2 on Days 1, 15, and 29; capecitabine 625 mg/m2 orally twice daily on days of radiotherapy)
Study: 34157617
Drug: CarPacRT (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CarPacRT (carboplatin AUC2; paclitaxel 50 mg/m2 on Days 1, 8, 15, 22, and 29)
Study: 33300239
Drug: Active, mandible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active, mandible protruded oral appliance (OAa)